Citizens Financial Group Inc. RI Acquires Shares of 50,000 Perspective Therapeutics, Inc. (NYSE:CATX)

Citizens Financial Group Inc. RI bought a new stake in Perspective Therapeutics, Inc. (NYSE:CATX) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 50,000 shares of the company’s stock, valued at approximately $160,000. Citizens Financial Group Inc. RI owned approximately 0.07% of Perspective Therapeutics as of its most recent SEC filing.

Other institutional investors also recently made changes to their positions in the company. Y Intercept Hong Kong Ltd bought a new stake in shares of Perspective Therapeutics in the fourth quarter worth $33,000. Aigen Investment Management LP bought a new stake in shares of Perspective Therapeutics in the 4th quarter worth about $34,000. Vontobel Holding Ltd. bought a new stake in shares of Perspective Therapeutics in the 4th quarter worth about $51,000. Trueblood Wealth Management LLC raised its stake in shares of Perspective Therapeutics by 37.0% in the 4th quarter. Trueblood Wealth Management LLC now owns 22,236 shares of the company’s stock valued at $71,000 after purchasing an additional 6,000 shares in the last quarter. Finally, Koa Wealth Management LLC bought a new position in shares of Perspective Therapeutics during the fourth quarter worth about $83,000. 54.66% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on CATX. Cantor Fitzgerald upgraded Perspective Therapeutics to a “strong-buy” rating in a research note on Tuesday, March 4th. Lifesci Capital raised Perspective Therapeutics to a “strong-buy” rating in a research report on Thursday, March 6th. Brookline Capital Management raised shares of Perspective Therapeutics to a “strong-buy” rating in a report on Monday, March 10th. Scotiabank initiated coverage on shares of Perspective Therapeutics in a research note on Friday, March 7th. They set a “sector outperform” rating and a $15.00 target price for the company. Finally, Royal Bank of Canada restated an “outperform” rating and issued a $16.00 price target on shares of Perspective Therapeutics in a research report on Tuesday, January 14th. One investment analyst has rated the stock with a hold rating, eight have given a buy rating and three have issued a strong buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Buy” and an average target price of $14.56.

Perspective Therapeutics Stock Performance

Shares of NYSE:CATX opened at $2.59 on Friday. The firm’s 50 day moving average is $3.14 and its two-hundred day moving average is $7.32. Perspective Therapeutics, Inc. has a 52 week low of $2.32 and a 52 week high of $19.05.

About Perspective Therapeutics

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.